{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "T",
                    "alt": "R",
                    "position": "240"
                },
                "variant_string_id": "PARK2 T240R"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR - JP) is characterized by selective dopaminergic neural cell death and absence of Lewy bodies. PARK2 mutations cause AR - JP, and parkin is involved in protein degradation as a ubiquitin - protein ligase. Accumulation of unidentified proteins may cause selective neural cell death.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes AR - JP's disease mechanism in relation to PARK2 and parkin's role in protein degradation, which is relevant to the functional assay of the variant.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "In vitro ubiquitination assays, immunoprecipitation, and cell - based assays were used to study parkin's function as an E3 ligase and the effect of mutants. These assays model the protein degradation process relevant to the disease mechanism of AR - JP.",
                    "judgment": "Yes",
                    "reasoning": "The assays used, such as in vitro ubiquitination and immunoprecipitation, are applicable as they directly relate to parkin's role in protein degradation, which is the disease mechanism defined in Step 1.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Basic Controls and Replicates: Not clear if multiple replicates were used. No mention of using both normal/negative/wild - type and abnormal/positive/null controls together. Sub - step 3b: Accepted/Validated Assay: The in vitro ubiquitination assay and immunoprecipitation are standard techniques in the field of protein - protein interaction and ubiquitination studies.",
                    "judgment": "Yes",
                    "reasoning": "Since basic controls and replicates information is insufficient, but the assays are broadly accepted in the field, this condition is met.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for PARK2 T240R is of supporting strength as the disease mechanism is defined, the assays are applicable, but basic controls and replicates are insufficient. However, the assays are well - accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "PARK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "P",
                    "position": "42"
                },
                "variant_string_id": "PARK2 R42P"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR - JP) is characterized by selective dopaminergic neural cell death and absence of Lewy bodies. PARK2 mutations cause AR - JP, and parkin is involved in protein degradation as a ubiquitin - protein ligase. Accumulation of unidentified proteins may cause selective neural cell death.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes AR - JP's disease mechanism in relation to PARK2 and parkin's role in protein degradation, which is relevant to the functional assay of the variant.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "In vitro ubiquitination assays, immunoprecipitation, and cell - based assays were used to study parkin's function as an E3 ligase and the effect of mutants. These assays model the protein degradation process relevant to the disease mechanism of AR - JP.",
                    "judgment": "Yes",
                    "reasoning": "The assays used, such as in vitro ubiquitination and immunoprecipitation, are applicable as they directly relate to parkin's role in protein degradation, which is the disease mechanism defined in Step 1.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Basic Controls and Replicates: Not clear if multiple replicates were used. No mention of using both normal/negative/wild - type and abnormal/positive/null controls together. Sub - step 3b: Accepted/Validated Assay: The in vitro ubiquitination assay and immunoprecipitation are standard techniques in the field of protein - protein interaction and ubiquitination studies.",
                    "judgment": "Yes",
                    "reasoning": "Since basic controls and replicates information is insufficient, but the assays are broadly accepted in the field, this condition is met.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for PARK2 R42P is of supporting strength as the disease mechanism is defined, the assays are applicable, but basic controls and replicates are insufficient. However, the assays are well - accepted in the field."
        }
    ]
}